VRCA Q1 2023 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,000-91.4% YoY

Gross Profit

-$31,000-83.8% margin

Operating Income

-$7M-19159.5% margin

Net Income

-$7M-17808.1% margin

EPS (Diluted)

$-1.53

QoQ Revenue Growth

-45.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$69M

Total Liabilities

$4M

Stockholders' Equity

$65M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,000	$431,000	-91.4%
Gross Profit	-$31,000	$153,000	-120.3%
Operating Income	-$7M	-$7M	+4.3%
Net Income	-$7M	-$8M	+22.2%